The widely used cough suppressant dextromethorphan is an NMDA receptor antagonist. Seyltx and Atlanta-based NeurOp are ...

RegenXBio has shared updated phase 1/2 data on its Duchenne muscular dystrophy (DMD) gene therapy, providing evidence that ...

Interim results from a small group of children in a Phase I/II trial are essentially in line with that of Elevidys, according ...

The Platform Technology Designation, which precedes the current FDA leadership, is designed to streamline the drug ...

The FDA has designated the viral vector rAAVrh74, which Sarepta Therapeutics, Inc. (NASDAQ:SRPT) uses in its gene therapy ...